Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Test and Treat strategy with Biktarvy in new HIV diagnoses in Barcelona
2019-004837-17Phase 3Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundació Clínic per a la Recerca Biomèdica. Started Mar 2020; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2019-004837-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004837-17.